MOR208C107 (First-MIND) (FL)

A phase Ib, open-label, randomized study to assess safety and preliminary efficacy of Tafasitamab in addition to R-CHOP or Tafasitamab plus Lenalidomide in addition to R-CHOP in patients with newly diagnosed Diffuse Large B-cell Lymphoma (DLBCL).

Study Treatments

R-CHOP + Tafasitamab (D1,8,15) vs R-CHOP + Tafasitamab (D1,8,15) + Lenalidomide (D1-10)

Inclusion criteria

• Confirmed diagnosis of DLBCL
• One measurable disease site, the lesion must be confirmed to be PET-positive.
• International Prognostic Index (IPI) status of 2 to 5
• Age >/= 18 years

Exclusion criteria

• Any other histological type of lymphoma, e.g. primary mediastinal large B-cell (PMBL), known double- or triple hit lymphoma or Burkitt’s lymphoma
• Transformed NHL and/or evidence of composite lymphoma
•  History of radiation therapy to >/= 25% of the bone marrow for other diseases or history of anthracycline therapy

Participating sites

• Jan Yperman
• UZ Gent
• ZNA Antwerpen